Vertex Pharmaceuticals to Acquire Crinetics for $10 Billion in Largest Deal Ever

Jul 6, 2026

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals on July 6, 2026, for approximately $10 billion in cash, marking the largest deal in Vertex's history. The $85-per-share price represents a 102% premium for Crinetics. The acquisition expands Vertex's portfolio into endocrinology, granting access to the FDA-approved acromegaly treatment Palsonify and the late-stage pipeline drug atumelnant, which together could generate over $5 billion in peak annual sales.

Vertex acquisition of Crinetics

▪The acquisition of Crinetics Pharmaceuticals is the largest deal in the history of Vertex Pharmaceuticals, surpassing its $4.4 billion purchase of Alpine Immune Sciences in 2024.
▪Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash, representing an equity value of about $85 per share.
▪The acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals is expected to close in the third quarter of 2026.
▪The purchase price of $85 per share represents a 102% premium over the closing price of Crinetics Pharmaceuticals stock on July 6, 2026.

Pharmaceutical M&A activity surge

▪Deep cash reserves, attractive biotech valuations, newly approved drugs, growing regulatory confidence, and patent losses are driving a wave of large pharmaceutical mergers and acquisitions in 2026.
▪The acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals represents one of the largest pharmaceutical deals of 2026.

Palsonify acromegaly treatment launch

▪Palsonify has shown early commercial momentum since its launch, according to Vertex Pharmaceuticals and Crinetics Pharmaceuticals.
▪The U.S. Food and Drug Administration approved Palsonify in September 2025 as a once-daily oral therapy to treat adults with acromegaly, a rare disorder caused by excess growth hormone.

Atumelnant CAH pipeline development

▪Vertex Pharmaceuticals and Crinetics Pharmaceuticals estimate that Palsonify and atumelnant could together generate more than $5 billion in peak annual sales.
▪Crinetics Pharmaceuticals is developing an experimental drug called atumelnant, which is in late-stage development for congenital adrenal hyperplasia.

Vertex portfolio diversification strategy

▪Vertex Pharmaceuticals, a dominant player in cystic fibrosis drugs, is seeking diversification through key growth areas including Casgevy and Journavx.
▪Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals to expand its portfolio into endocrinology and treatments for rare hormonal diseases.
▪Vertex Pharmaceuticals expects the Crinetics Pharmaceuticals acquisition to add immediately to revenue growth and become accretive to adjusted operating income in 2029.